Claudine E. Bruck
Founder of Prolifagen LLC, Claudine E. Bruck currently is Chief Scientific Officer of SapVax LLC. She is also on the board of Annovis Bio, Inc.
In the past she held the position of Chief Executive Officer at Prolifagen LLC, Head-Cancer Vaccine Program at GlaxoSmithKline LLC, Course Director at the University of Pennsylvania and Assistant Professor at Tufts University School of Medicine.
She received a doctorate from Vrije Universiteit Brussel and a graduate degree from Harvard Medical School.
Transactions
Date
Transaction
Value
| 10/11/2021 | 181 | Acquisition at $27.66 per share. | 5,006 |
| 01/31/2020 | 1,117 | Derivative/Non-derivative trans. at $4.8 per share. | 5,361 |
| 01/31/2020 | 3,969 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/31/2020 | 800 | Acquisition at $6 per share. | 4,800 |
